Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. 1987

K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa

Tissue factor activity (TFA) of 10(8) leukemia cells was measured in 82 patients with acute nonlymphoid leukemia by the clotting method. The TFA bore a significant correlation to the development of disseminated intravascular coagulation (DIC) in these cases. Mean TFA value with standard deviation (SD) was 8.3 +/- 6.3 U in 48 cases with DIC, which was significantly higher than 0.3 +/- 4.2 U in 34 cases without DIC. Whereas Mean TFA in non-M3 was 0.9 +/- 6.3 U which was significantly lower than 37.2 +/- 2.3 U in M3, some non-M3 showed TFA as high as M3 and were complicated by DIC. In heparin treatment, dosage of heparin could not be controlled by either APTT or AcCT but was controlled by the extent of TFA of leukemia cells. Retrospective analysis of clinical features revealed that 97000X + 9000 units/day (X = logarithm value of TFA) of heparin is an adequate dosage for the successful treatment of DIC when TFA of leukemia cells is 0.8 U or more.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
April 1980, Rinsho byori. The Japanese journal of clinical pathology,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
May 1990, American journal of clinical pathology,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
February 1982, Rinsho byori. The Japanese journal of clinical pathology,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
May 1999, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
May 1973, Revista clinica espanola,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
May 1965, Military medicine,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
January 2020, The Journal of veterinary medical science,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
March 1981, Annals of tropical paediatrics,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
November 1995, Thrombosis research,
K Andoh, and T Kubota, and M Takada, and H Tanaka, and N Kobayashi, and T Maekawa
December 2001, Seminars in thrombosis and hemostasis,
Copied contents to your clipboard!